– Study will compare the acute subjective, physiological, and endocrine effects of R-MDMA, S-MDMA, and racemic MDMA in 24 healthy subjects – NEW YORK, Oct. 4, 2022 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the initiation…


Previous articleKetaMD Expands Access to Breakthrough Ketamine Therapy in Florida to Battle the Growing Mental Health Crisis and Shortage of Mental Health Care Providers
Next articleatai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT